Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2010
|
| gptkbp:ATCCode |
N05AE05
|
| gptkbp:CASNumber |
367514-87-2
|
| gptkbp:chemicalFormula |
C28H36N4O2S
|
| gptkbp:contraindication |
strong CYP3A4 inducers
strong CYP3A4 inhibitors |
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:lurasidone
|
| https://www.w3.org/2000/01/rdf-schema#label |
Latuda
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sumitomo_Dainippon_Pharma
|
| gptkbp:marketedIn |
gptkb:Canada
gptkb:Europe gptkb:United_States |
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
weight gain restlessness drowsiness akathisia |
| gptkbp:usedFor |
schizophrenia
bipolar depression |
| gptkbp:bfsParent |
gptkb:Sumitomo_Pharma
gptkb:Sumitomo_Dainippon_Pharma |
| gptkbp:bfsLayer |
6
|